Opendata, web and dolomites

IMMUNOMARK SIGNED

Omics integration for precision cancer immunotherapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 IMMUNOMARK project word cloud

Explore the words cloud of the IMMUNOMARK project. It provides you a very rough idea of what is the project "IMMUNOMARK" about.

monitor    l1    immunologic    wp2    line    multilayer    integrating    total    linked    post    treatment    detection    epigenetic    biological    validation    cd56    marks    blood    health    structure    signature    fac    urgent    wp1    definite    metastatic    expressed    melanoma    proteins    clinical    predictive    mapping    biopsies    differentially    identification    parts    methylation    disease    sorted    samples    tumor    provides    rational    agents    tested    biopsy    transcriptomics    genome    beginning    cell    immunotherapies    followed    detect    therapy    pd    genes    checkpoint    integrative    era    invasively    elucidate    tissues    limited    cancer    prevent    anti    cells    responders    cd8    definitive    innovation    genetic    omics    treat    biomarkers    liquid    revolution    circulating    lung    patients    lack    multiple    amenable    30    solid    innovative    horizon    cohort    ctla4    stroma    2020    small    outcome    immunotherapy    applies    inhibitors   

Project "IMMUNOMARK" data sheet

The following table provides information about the project.

Coordinator
FUNDACION PUBLICA ANDALUZA PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD 

Organization address
address: CALLE DOCTOR MIGUEL DIAZ RECIO 28 PLANTA BAJA
city: MALAGA
postcode: 29010
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 170˙121 €
 EC max contribution 170˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-03-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACION PUBLICA ANDALUZA PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD ES (MALAGA) coordinator 170˙121.00

Map

 Project objective

The development of immunotherapies based on checkpoint inhibitors marks the beginning of a new era in the treatment of cancer, with 20-30% of tumor response in advanced non–small-cell lung cancer and melanoma. However, the rational use of these agents has been limited by the lack of definitive predictive biomarkers. The recent “omics revolution” provides great opportunities to elucidate the biological processes linked to the treatment outcome. Here we propose a multilayer integrative omics analysis using transcriptomics and genetic and epigenetic mapping, together with detection of specific immunologic proteins, to identify biomarkers of clinical response to immunotherapy amenable to be used in liquid biopsies. Objective: to identify definite biomarkers predictive of the response to anti-PD-1, anti-PD-L1, and anti-CTLA4 therapy in patients with metastatic melanoma and advanced non–small-cell lung cancer. We structure the proposal in two parts: WP1. Signature of response to the immunotherapy by integrating transcriptomics and genetic and epigenetic mapping in tumor tissues: solid biopsy. Genome-wide transcriptomics on FAC-sorted tumor and stroma cells followed by targeted genetic and epigenetic mapping in the differentially expressed genes in responders. WP2: Identification of circulating biomarkers of response to the immunotherapy: liquid biopsy. Pre- and post-treatment blood samples from a validation cohort will be used as liquid biopsy. Genetic and epigenetic biomarkers of WP1 will be tested as circulating biomarkers. In addition, LINE-1 methylation, total Circulating Tumor Cells, CD56, or CD8 PD-1 cells will be tested. This project applies multiple innovative approaches to address the urgent need of identifying biomarkers of clinical response to immunotherapy in cancer, amenable to be used non-invasively. In line with the Horizon 2020 Research & Innovation goal, we will “improve our ability to monitor health and to prevent, detect, treat and manage disease.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUNOMARK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMUNOMARK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

Photonic Radar (2019)

Implementation of Long Reach Hybrid Photonic Radar System and convergence over FSO and PON Networks

Read More  

CORRELATION (2020)

Characterization and prediction of service-level traffic for future sliced mobile network

Read More  

MarshFlux (2020)

The effect of future global climate and land-use change on greenhouse gas fluxes and microbial processes in salt marshes

Read More